This article is more than 5 years old. Information may no longer be current.

CoMentis initiates phase 2 trial of topical AMD drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SOUTH SAN FRANCISCO, Calif. — CoMentis Inc. has initiated a phase 2 clinical study evaluating a topical ophthalmic formulation of mecamylamine for treating neovascular age-related macular degeneration, the company announced in a press release.

The drug, called ATG3, is an antagonist of the nicotinic acetylcholine receptor pathway that mediates angiogenesis. The drug was developed to penetrate into the retina and choroid after administration via eye drops, the release said.

This phase 2 study will evaluate the safety and efficacy of ATG3 in about 330 wet AMD patients randomly assigned to either twice daily drug applications at one of two concentrations or to placebo. Only one eye of each patient will be treated, and patients will be followed for 48 weeks.

A phase 1 study completed in January, which involved healthy subjects, found a good ocular safety profile for the drug. Company officials expect to have interim 6-month efficacy results of the new trial by mid-2008, according to the release.